1438 related articles for article (PubMed ID: 28359548)
1. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
2. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease.
Kawanaka M; Nishino K; Nakamura J; Urata N; Oka T; Goto D; Suehiro M; Kawamoto H; Yamada G
Ann Hepatol; 2015; 14(6):837-44. PubMed ID: 26436355
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
[TBL] [Abstract][Full Text] [Related]
8. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
[TBL] [Abstract][Full Text] [Related]
9. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
[TBL] [Abstract][Full Text] [Related]
10. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
[TBL] [Abstract][Full Text] [Related]
11. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
[TBL] [Abstract][Full Text] [Related]
13. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
[TBL] [Abstract][Full Text] [Related]
14. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
15. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.
Diab DL; Yerian L; Schauer P; Kashyap SR; Lopez R; Hazen SL; Feldstein AE
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1249-54. PubMed ID: 18995215
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ
Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease.
Kim YS; Jung ES; Hur W; Bae SH; Choi JY; Song MJ; Kim CW; Jo SH; Lee CD; Lee YS; Choi SW; Yang JM; Jang JW; Kim SG; Jung SW; Kim HK; Chae HB; Yoon SK
Clin Mol Hepatol; 2013 Jun; 19(2):120-30. PubMed ID: 23837136
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
20. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
